Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29800289 | 1.00 | PTGS2 (0.48) | PTGS2ABL1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL10610948 | 0.86 | ABL1 (0.49) | PTGS2ABL1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL31636728 | 0.85 | PTGS2 (0.48) | PTGS2ABL1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL523584 | 0.83 | ABL1 (0.57) | ABL1MAPTSMN1; SMN2NPC1NFKB1 | |
| SCHEMBL8492639 | 0.81 | ABL1 (0.45) | PTGS2ABL1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL29151120 | 0.81 | ABL1 (0.45) | PTGS2ABL1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL8135257 | 0.81 | GAA (0.46) | PTGS2ABL1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL1578948 | 0.81 | ABL1 (0.57) | PTGS2ABL1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL2264277 | 0.81 | ABL1 (0.53) | PTGS2ABL1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL29151091 | 0.81 | ABL1 (0.41) | PTGS2ABL1MAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114957056-A | Process for preparing methyl 3-methyl-2-chloro-4-methylsulfonylbenzoate and intermediates thereof | 帕潘纳(北京)科技有限公司 | 2022-08-30 | — | — | CN | claimed |
| CN-112409226-B | Substituted benzoyl compounds and application thereof | 东莞市东阳光农药研发有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-112409263-B | Substituted benzoyl compounds and application thereof | 东莞市东阳光农药研发有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-112174889-B | Substituted benzoyl compounds and application thereof in agriculture | 东莞市东阳光农药研发有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-112142671-B | Substituted benzoyl-pyrazoles and application thereof in agriculture | 东莞市东阳光农药研发有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-112300092-B | Heterocyclylalkyl-substituted dichlorobenzoyl compounds and application thereof | 东莞市东阳光农药研发有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| CN-114957056-A | Process for preparing methyl 3-methyl-2-chloro-4-methylsulfonylbenzoate and intermediates thereof | 帕潘纳(北京)科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114957056-A | Process for preparing methyl 3-methyl-2-chloro-4-methylsulfonylbenzoate and intermediates thereof | 帕潘纳(北京)科技有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-7112554-B2 | Substituted arylketones | BAYER CROPSCIENCE AG (DE) | 2006-09-26 | — | — | US | disclosed |
| EP-1611098-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089897-A1 | COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
| US-20040176253-A1 | Substitued arylketones | BAYER CROPSCIENCE AG (DE) | 2004-09-09 | — | — | US | disclosed |
| US-6576596-B1 | Compatible with crop plants | BASF AKTIENGESELLSCHAFT (DE) | 2003-06-10 | — | — | US | disclosed |
| US-6372693-B1 | AGRICULTURAL HERBICIDES FOR CONTROLLING WEEDS | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-16 | — | — | US | disclosed |
| US-6310245-B1 | FOR CONTROLLING UNDESIRABLE VEGETATION; CROP PROTECTION | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-30 | — | — | US | disclosed |
| US-6143696-A | FOR CROP PROTECTION; HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | disclosed |
| US-6133468-A | BROMINATION OF SUBSTITUTED TOLUENES WITH A BROMINATING AGENT SELECTED FROM THE GROUP CONSISTING OF BROMINE, BROMINE SALTS AND HYDROGEN BROMIDE, IN THE PRESENCE OF AN AZO CARBONITRILE OR OF AN AZO CARBOXYLIC ESTER | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | disclosed |
| US-6028035-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176253-A1 | Substitued arylketones | CYP1B1, CYP1A1, CYP2E1 | PTGS2 3744/4885ABL1 132/4885MAPT 3749/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | PTGS2 467/4885ABL1 1932/4885MAPT 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.